The stock of Revance Therapeutics Inc (NASDAQ:RVNC) is a huge mover today! About 127,347 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 16.67% since March 10, 2016 and is downtrending. It has underperformed by 24.19% the S&P500.
The move comes after 6 months positive chart setup for the $401.62M company. It was reported on Oct, 13 by Barchart.com. We have $32.70 PT which if reached, will make NASDAQ:RVNC worth $469.90 million more.
Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on November, 14. They expect $-0.90 EPS, down 11.11% or $0.09 from last year’s $-0.81 per share. After $-0.88 actual EPS reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.27% negative EPS growth.
Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage
Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. Suntrust Robinson maintained Revance Therapeutics Inc (NASDAQ:RVNC) rating on Tuesday, June 14. Suntrust Robinson has “Buy” rating and $22 price target. As per Wednesday, March 23, the company rating was initiated by SunTrust. Zacks downgraded the shares of RVNC in a report on Saturday, August 22 to “Hold” rating. The firm has “Hold” rating given on Tuesday, June 14 by Brean Capital. The stock of Revance Therapeutics Inc (NASDAQ:RVNC) earned “Buy” rating by Guggenheim on Monday, November 23.
According to Zacks Investment Research, “Revance Therapeutics, Inc. is a biopharmaceutical company which focuses on the development, manufacture and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications. The company’s technology platform includes TransMTS (R). Its lead product candidate consists of RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow’s feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. Revance Therapeutics, Inc. is based in Newark, United States.”
Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.32, from 1.07 in 2016Q1. The ratio improved, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Goldman Sachs Group has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Ladenburg Thalmann Serv has 0% invested in the company for 12 shares. Nottingham Advisors Inc accumulated 16,312 shares or 0.04% of the stock. Essex Woodlands Health Ventures Inc holds 15.74% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 4.59 million shares. Morgan Stanley holds 90,037 shares or 0% of its portfolio. Deutsche National Bank Ag has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Swiss Bancorp holds 0% or 30,750 shares in its portfolio. Nationwide Fund Advsr reported 33,556 shares or 0% of all its holdings. Moreover, Arrowpoint Asset Limited Liability Corporation has 0.46% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 1.67 million shares. Fincl Bank Of America De has 3,592 shares for 0% of their US portfolio. Teachers accumulated 32,072 shares or 0% of the stock. New York State Common Retirement Fund holds 18,900 shares or 0% of its portfolio. Moreover, Blackrock Gru Limited has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 6,137 shares. Jacobs Levy Equity Management holds 0.01% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 51,400 shares. Moreover, Finemark Bancorp Tru has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 1,000 shares.
Insider Transactions: Since May 9, 2016, the stock had 0 insider purchases, and 2 selling transactions for $34,430 net activity. Ruegg Curtis had sold 1,000 shares worth $18,250.
Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.
RVNC Company Profile
Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.